HPV E6-specific TCR-T cells

N/A

Report date: 2022/09/05 18:01:15

Base Information

Drug NameHPV E6-specific TCR-T cells
Drug Alias NameSIM-325TC-E202E202
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsImmunostimulantsProtein E6 modulators
TargetsProtein E6
Therapy Area/IndicationsUterine Cervical NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTcrcure Biopharma Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTcrcure Biopharma LtdThe Second Affiliated Hospital of Army Medical University
Inactive CompaniesSimcere Pharmaceutical Group Ltd
Active IndicationsUterine Cervical NeoplasmsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A